Transactivation of human parvovirus B19 gene expression in endothelial cells by adenoviral helper functions

Virology

Volumn 411, Issue 1, 2011, Pages 50-64

  Pozzuto, Tanja ^a   von Kietzell, Kristina ^a   Bock, Thomas ^b   Schmidt Lucke, Caroline ^a   Poller, Wolfgang ^a   Zobel, Thomas ^c   Lassner, Dirk ^c   Zeichhardt, Heinz ^a   Weger, Stefan ^a   Fechner, Henry ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c Institute of Cardiac Diagnostics and Therapy (IKDT)   (Germany)

Author keywords

Adenovirus; B19V; Cardiomyopathy; E1A; E4orf6; Endothelial cells; Gene expression; Replication; Transactivation

Indexed keywords

E1A PROTEIN; MESSENGER RNA; SINGLE STRANDED DNA; VIRUS PROTEIN;

ADENOVIRUS 2; ADENOVIRUS 5; ARTICLE; CARDIOMYOPATHY; CHRONIC DISEASE; CONTROLLED STUDY; DNA REPLICATION; DNA TEMPLATE; EMBRYO; ENDOTHELIUM CELL; GENE ACTIVATION; GENE EXPRESSION REGULATION; HEART MUSCLE BIOPSY; HELPER VIRUS; HUMAN; HUMAN ADENOVIRUS INFECTION; HUMAN CELL; HUMAN PARVOVIRUS B19; HUMAN TISSUE; NONHUMAN; NUCLEOTIDE SEQUENCE; PARVOVIRUS INFECTION; PRIORITY JOURNAL; PROCESS MODEL; PROMOTER REGION; PROTEIN EXPRESSION; SUPERINFECTION; TRANSACTIVATION; VIRAL TROPISM; VIRUS CAPSID; VIRUS CELL INTERACTION; VIRUS GENE; VIRUS GENOME; VIRUS INDUCTION; VIRUS ISOLATION; VIRUS MYOCARDITIS; VIRUS PARTICLE; VIRUS PATHOGENESIS; VIRUS REPLICATION;

ADENOVIRUS E1A PROTEINS; ADENOVIRUS E4 PROTEINS; ADENOVIRUSES, HUMAN; CELLS, CULTURED; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION, VIRAL; HUMANS; PARVOVIRUS B19, HUMAN; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION; VIRAL PROTEINS;

ADENOVIRIDAE; PARVOVIRUS;

EID: 79551687658     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2010.12.019     Document Type: Article

References (53)

1. Anderson M.J., Higgins P.G., Davis L.R., Willman J.S., Jones S.E., Kidd I.M., Pattison J.R., Tyrrell D.A. Experimental parvoviral infection in humans. J. Infect. Dis. 1985, 152(2):257-265.
2. Babiss L.E., Ginsberg H.S., Darnell J.E. Adenovirus E1B proteins are required for accumulation of late viral mRNA and for effects on cellular mRNA translation and transport. Mol. Cell. Biol. 1985, 5(10):2552-2558.
3. Berk A.J. Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus. Oncogene 2005, 24(52):7673-7685.
4. Berk A.J., Lee F., Harrison T., Williams J., Sharp P.A. Pre-early adenovirus 5 gene product regulates synthesis of early viral messenger RNAs. Cell 1979, 17(4):935-944.
5. Bock C.T. Parvovirus B19: a new emerging pathogenic agent of inflammatory cardiomyopathy. Ernst Schering Res. Found. Workshop 2006, 55:83-97.
6. Bock C.T., Klingel K., Kandolf R. Human parvovirus B19-associated myocarditis. N. Engl. J. Med. 2010, 362(13):1248-1249.
7. Boyer T.G., Martin M.E., Lees E., Ricciardi R.P., Berk A.J. Mammalian Srb/Mediator complex is targeted by adenovirus E1A protein. Nature 1999, 399(6733):276-279.
8. Brown K.E., Anderson S.M., Young N.S. Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science 1993, 262(5130):114-117.
9. Bultmann B.D., Klingel K., Sotlar K., Bock C.T., Baba H.A., Sauter M., Kandolf R. Fatal parvovirus B19-associated myocarditis clinically mimicking ischemic heart disease: an endothelial cell-mediated disease. Hum. Pathol. 2003, 34(1):92-95.
10. Cantin G.T., Stevens J.L., Berk A.J. Activation domain-mediator interactions promote transcription preinitiation complex assembly on promoter DNA. Proc. Natl Acad. Sci. USA 2003, 100(21):12003-12008.
11. Cotmore S.F., Tattersall P. Structure and organization of the viral genome. Parvoviruses 2005, 73-94. Hodder Arnold, London, United Kingdom. J.R. Kerr, S.F. Cotmore, M.E. Bloom, R.M. Linden, C.R. Parrish (Eds.).
12. de Wet J.R., Wood K.V., DeLuca M., Helinski D.R., Subramani S. Firefly luciferase gene: structure and expression in mammalian cells. Mol. Cell. Biol. 1987, 7(2):725-737.
13. Doerig C., Hirt B., Antonietti J.P., Beard P. Nonstructural protein of parvoviruses B19 and minute virus of mice controls transcription. J. Virol. 1990, 64(1):387-396.
14. Duechting A., Tschope C., Kaiser H., Lamkemeyer T., Tanaka N., Aberle S., Lang F., Torresi J., Kandolf R., Bock C.T. Human parvovirus B19 NS1 protein modulates inflammatory signaling by activation of STAT3/PIAS3 in human endothelial cells. J. Virol. 2008, 82(16):7942-7952.
15. Fechner H., Haack A., Wang H., Wang X., Eizema K., Pauschinger M., Schoemaker R., Veghel R., Houtsmuller A., Schultheiss H.P., Lamers J., Poller W. Expression of coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers. Gene Ther. 1999, 6(9):1520-1535.
16. Fechner H., Wang X., Wang H., Jansen A., Pauschinger M., Scherubl H., Bergelson J.M., Schultheiss H.P., Poller W. Trans-complementation of vector replication versus Coxsackie-adenovirus-receptor overexpression to improve transgene expression in poorly permissive cancer cells. Gene Ther. 2000, 7(22):1954-1968.
17. Fechner H., Wang X., Srour M., Siemetzki U., Seltmann H., Sutter A.P., Scherubl H., Zouboulis C.C., Schwaab R., Hillen W., Schultheiss H.P., Poller W. A novel tetracycline-controlled transactivator-transrepressor system enables external control of oncolytic adenovirus replication. Gene Ther. 2003, 10(19):1680-1690.
18. Ferrari F.K., Samulski T., Shenk T., Samulski R.J. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J. Virol. 1996, 70(5):3227-3234.
19. Gareus R., Gigler A., Hemauer A., Leruez-Ville M., Morinet F., Wolf H., Modrow S. Characterization of cis-acting and NS1 protein-responsive elements in the p6 promoter of parvovirus B19. J. Virol. 1998, 72(1):609-616.
20. Guan W., Cheng F., Yoto Y., Kleiboeker S., Wong S., Zhi N., Pintel D.J., Qiu J. Block to the production of full-length B19 virus transcripts by internal polyadenylation is overcome by replication of the viral genome. J. Virol. 2008, 82(20):9951-9963.
21. Guan W., Wong S., Zhi N., Qiu J. The genome of human parvovirus b19 can replicate in nonpermissive cells with the help of adenovirus genes and produces infectious virus. J. Virol. 2009, 83(18):9541-9553.
22. Heegaard E.D., Brown K.E. Human parvovirus B19. Clin. Microbiol. Rev. 2002, 15(3):485-505.
23. Klingel K., Sauter M., Bock C.T., Szalay G., Schnorr J.J., Kandolf R. Molecular pathology of inflammatory cardiomyopathy. Med. Microbiol. Immunol. 2004, 193(2-3):101-107.
24. Kuhl U., Pauschinger M., Noutsias M., Seeberg B., Bock T., Lassner D., Poller W., Kandolf R., Schultheiss H.P. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with "idiopathic" left ventricular dysfunction. Circulation 2005, 111(7):887-893.
25. Larsen P.L., Tibbetts C. Adenovirus E1A gene autorepression: revertants of an E1A promoter mutation encode altered E1A proteins. Proc. Natl Acad. Sci. USA 1987, 84(23):8185-8189.
26. Leppard K.N., Shenk T. The adenovirus E1B 55 kd protein influences mRNA transport via an intranuclear effect on RNA metabolism. EMBO J. 1989, 8(8):2329-2336.
27. Liu J.M., Fujii H., Green S.W., Komatsu N., Young N.S., Shimada T. Indiscriminate activity from the B19 parvovirus p6 promoter in nonpermissive cells. Virology 1991, 182(1):361-364.
28. Liu J.M., Green S.W., Shimada T., Young N.S. A block in full-length transcript maturation in cells nonpermissive for B19 parvovirus. J. Virol. 1992, 66(8):4686-4692.
29. McCarty D.M., Monahan P.E., Samulski R.J. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther. 2001, 8(16):1248-1254.
30. Munakata Y., Saito-Ito T., Kumura-Ishii K., Huang J., Kodera T., Ishii T., Hirabayashi Y., Koyanagi Y., Sasaki T. Ku80 autoantigen as a cellular coreceptor for human parvovirus B19 infection. Blood 2005, 106(10):3449-3456.
31. Ozawa K., Kurtzman G., Young N. Replication of the B19 parvovirus in human bone marrow cell cultures. Science 1986, 233(4766):883-886.
32. Ozawa K., Ayub J., Hao Y.S., Kurtzman G., Shimada T., Young N. Novel transcription map for the B19 (human) pathogenic parvovirus. J. Virol. 1987, 61(8):2395-2406.
33. Pasquinelli G., Bonvicini F., Foroni L., Salfi N., Gallinella G. Placental endothelial cells can be productively infected by Parvovirus B19. J. Clin. Virol. 2009, 44(1):33-38.
34. Ponnazhagan S., Woody M.J., Wang X.S., Zhou S.Z., Srivastava A. Transcriptional transactivation of parvovirus B19 promoters in nonpermissive human cells by adenovirus type 2. J. Virol. 1995, 69(12):8096-8101.
35. Ponnazhagan S., Wang X.S., Woody M.J., Luo F., Kang L.Y., Nallari M.L., Munshi N.C., Zhou S.Z., Srivastava A. Differential expression in human cells from the p6 promoter of human parvovirus B19 following plasmid transfection and recombinant adeno-associated virus 2 (AAV) infection: human megakaryocytic leukaemia cells are non-permissive for AAV infection. J. Gen. Virol. 1996, 77(Pt 6):1111-1122.
36. Raychaudhuri P., Bagchi S., Devoto S.H., Kraus V.B., Moran E., Nevins J.R. Domains of the adenovirus E1A protein required for oncogenic activity are also required for dissociation of E2F transcription factor complexes. Genes Dev. 1991, 5(7):1200-1211.
37. Richardson W.D., Westphal H. A cascade of adenovirus early functions is required for expression of adeno-associated virus. Cell 1981, 27(1 Pt 2):133-141.
38. Rittner K., Stöppler H., Pawlita M., Sczakiel G. Versatile eukaryotic vectors for strong and constitutive transient and stable gene expression. Meth. Mol. Cell. Biol. 1991, 2:176-181.
39. Samulski R.J., Shenk T. Adenovirus E1B 55-Mr polypeptide facilitates timely cytoplasmic accumulation of adeno-associated virus mRNAs. J. Virol. 1988, 62(1):206-210.
40. Shimomura S., Komatsu N., Frickhofen N., Anderson S., Kajigaya S., Young N.S. First continuous propagation of B19 parvovirus in a cell line. Blood 1992, 79(1):18-24.
41. Smith D.H., Kegler D.M., Ziff E.B. Vector expression of adenovirus type 5 E1a proteins: evidence for E1a autoregulation. Mol. Cell. Biol. 1985, 5(10):2684-2696.
42. Srivastava A., Lu L. Replication of B19 parvovirus in highly enriched hematopoietic progenitor cells from normal human bone marrow. J. Virol. 1988, 62(8):3059-3063.
43. Srivastava C.H., Samulski R.J., Lu L., Larsen S.H., Srivastava A. Construction of a recombinant human parvovirus B19: adeno-associated virus 2 (AAV) DNA inverted terminal repeats are functional in an AAV-B19 hybrid virus. Proc. Natl Acad. Sci. USA 1989, 86(20):8078-8082.
44. Tschope C., Bock C.T., Kasner M., Noutsias M., Westermann D., Schwimmbeck P.L., Pauschinger M., Poller W.C., Kuhl U., Kandolf R., Schultheiss H.P. High prevalence of cardiac parvovirus B19 infection in patients with isolated left ventricular diastolic dysfunction. Circulation 2005, 111(7):879-886.
45. Weger S., Wistuba A., Grimm D., Kleinschmidt J.A. Control of adeno-associated virus type 2 cap gene expression: relative influence of helper virus, terminal repeats, and Rep proteins. J. Virol. 1997, 71(11):8437-8447.
46. Weigel-Kelley K.A., Yoder M.C., Srivastava A. Recombinant human parvovirus B19 vectors: erythrocyte P antigen is necessary but not sufficient for successful transduction of human hematopoietic cells. J. Virol. 2001, 75(9):4110-4116.
47. Weigel-Kelley K.A., Yoder M.C., Srivastava A. Alpha5beta1 integrin as a cellular coreceptor for human parvovirus B19: requirement of functional activation of beta1 integrin for viral entry. Blood 2003, 102(12):3927-3933.
48. Yoto Y., Qiu J., Pintel D.J. Identification and characterization of two internal cleavage and polyadenylation sites of parvovirus B19 RNA. J. Virol. 2006, 80(3):1604-1609.
49. Zakrzewska K., Cortivo R., Tonello C., Panfilo S., Abatangelo G., Giuggioli D., Ferri C., Corcioli F., Azzi A. Human parvovirus B19 experimental infection in human fibroblasts and endothelial cells cultures. Virus Res. 2005, 114(1-2):1-5.
50. Zhi N., Zadori Z., Brown K.E., Tijssen P. Construction and sequencing of an infectious clone of the human parvovirus B19. Virology 2004, 318(1):142-152.
51. Zolotukhin S., Potter M., Hauswirth W.W., Guy J., Muzyczka N.A "humanized" green fluorescent protein cDNA adapted for high-level expression in mammalian cells. J. Virol. 1996, 70(7):4646-4654.
52. Zolotukhin S., Byrne B.J., Mason E., Zolotukhin I., Potter M., Chesnut K., Summerford C., Samulski R.J., Muzyczka N. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 1999, 6(6):973-985.
53. Zolotukhin S., Potter M., Zolotukhin I., Sakai Y., Loiler S., Fraites T.J., Chiodo V.A., Phillipsberg T., Muzyczka N., Hauswirth W.W., Flotte T.R., Byrne B.J., Snyder R.O. Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 2002, 28(2):158-167.